Is mRNA in Livestock Safe? Exploring SEQUIVITY's Impact

The use of mRNA technology in livestock is no longer speculative—it’s active. Pork producers have already adopted mRNA-based injections like SEQUIVITY® to combat swine diseases. While the technology differs slightly from the human COVID injections, the core mechanism is the same: programming the body to produce synthetic proteins using lab-generated genetic instructions.

These aren’t traditional vaccines. There’s no attenuated virus. There’s no immune response to a natural pathogen. What’s happening—whether in humans or animals—is the internal manufacturing of an artificial protein based on computer-modeled genetic code.

This raises a serious question: what happens when people eat meat from animals injected with mRNA technology?

Regulatory agencies and industry representatives claim it’s safe. They say the mRNA breaks down before it reaches your plate. They also said the spike protein in COVID shots would stay in the arm, that it wouldn’t shed, and that it posed no reproductive risk. All of that has since been challenged by peer-reviewed research, independent analyses, and thousands of real-world adverse events.

What we do know is that the spike protein created by the COVID injections is transmissible. It sheds through sweat, saliva, semen, and vaginal fluids. It’s been linked to reproductive harm, cardiovascular issues, and neurological inflammation. This isn’t theory—it’s being reported in medical literature and acknowledged by doctors who were silenced early on.

The concern now is simple: if synthetic proteins created by mRNA can shed from one human to another, what happens when a human consumes animal tissue that has been producing a different synthetic protein? There is no long-term data to answer that question. No independent testing. No transparent labeling. No public consent.

The burden of proof doesn’t fall on those raising the alarm—it falls on the institutions forcing this technology into the food chain without proper oversight. The meat industry is quietly shifting toward mRNA-based injections while consumers are kept in the dark. Those who refused the shot are now being exposed by default, without their knowledge or consent.

This isn’t about fear. It’s about informed decision-making and the right to control what enters your body. If you opted out of the COVID injection, you should have the right to avoid exposure through your food as well.
But you can’t make that choice if you’re not even told it’s happening.

mRNA Technology in Livestock: Examining the Evidence about SEQUIVITY and Swine Vaccines

The development and application of RNA-based vaccines in livestock has emerged as a significant advancement in animal health management, particularly in the swine industry. This report examines the current state of RNA technology in livestock vaccines, with a focus on the SEQUIVITY platform and how it compares to human mRNA vaccines.

Current Status of RNA Technology in Swine Health Management

RNA-based vaccine technology has indeed moved beyond the speculative phase and into active implementation within the livestock industry, specifically in swine production. Merck Animal Health’s SEQUIVITY platform represents the primary commercially available RNA-based vaccine technology for swine in the United States^[1]^[2]. This platform has been in use for a considerable period, with millions of doses administered to swine herds since receiving USDA licensing in 2012^[3].

The SEQUIVITY platform is described as a “revolutionary swine vaccine platform” that “harnesses RNA particle technology” to create customized prescription vaccines targeting various swine diseases^[1]. In March 2024, Merck Animal Health announced USDA license approval for SEQUIVITY with Microsol Diluvac Forte (MDF) adjuvant prescription vaccine specifically for use in gilts and sows^[4]. This development expanded the application of their RNA particle technology in swine health management.

Target Diseases and Applications

The SEQUIVITY platform has been developed to address multiple swine pathogens, creating custom prescription products for:

Porcine circovirus type 2 (PCV2) vaccines
Porcine circovirus type 3 (PCV3) vaccines
Rotavirus vaccines
Sapovirus vaccines
Influenza A virus in swine (IAV-S) vaccines
Porcine epidemic diarrhea (PED) vaccines^[1]

Technology Comparison: SEQUIVITY vs. Human COVID mRNA Vaccines

While both SEQUIVITY and human COVID-19 vaccines utilize RNA technology, it’s important to distinguish between their specific mechanisms and classifications.

RNA Particles vs. mRNA Vaccines

The SEQUIVITY platform uses what Merck Animal Health describes as “RNA Particle Technology,” which contains RNA Particles (RP) that produce antigens to stimulate a protective immune response in animals^[3]. However, veterinary and agricultural experts make an important technical distinction: SEQUIVITY is described as an “RNA vaccine” rather than specifically an “mRNA vaccine” like those developed for COVID-19^[5].

As Rod Johnson, head of the Department of Animal Sciences at the University of Illinois explains, in the COVID vaccine, “the messenger RNA, or mRNA, gets inside the host cell and provides instructions to produce a specific protein. The host cells start producing the ‘spike’ protein; then our immune system recognizes it as foreign and develops antibodies to protect us”^[6]. While SEQUIVITY operates on RNA principles, experts clarify that “there are no animal vaccines currently licensed in the U.S. that use the same mRNA approach as the human COVID-19 vaccine”^[6].

Mechanism and Functionality

There are similarities in the fundamental concept that both technologies use RNA to stimulate an immune response. The SEQUIVITY technology is described as “targeted” in that it “only targets swine pathogen gene sequences of interest”^[1]. The platform creates vaccines that are “safe” because they “doesn’t replicate or cause disease, delivering pathogen information to the immune system safely”^[1].

Research into other potential mRNA vaccines for swine demonstrates a mechanism closer to human COVID vaccines. For example, studies have examined lipid nanoparticle (LNP)-encapsulated mRNA vaccines that encode viral proteins like the full-length PEDV spike protein to induce immunity against porcine epidemic diarrhea virus^[7]. These experimental approaches more closely mirror the human COVID vaccine mechanism.

Expert Perspectives and Regulatory Status

The National Association of State Departments of Agriculture (NASDA) has formally supported farmers’ access to approved vaccine technologies, including mRNA vaccines when properly developed and licensed^[5]. NASDA CEO Ted McKinney emphasized, “NASDA prioritizes the wellbeing of livestock and public health, and we must ensure farmers and ranchers have access to approved mRNA vaccines to ensure the health of their animals and provide a safe and resilient food supply”^[5].

However, experts consistently emphasize several important points regarding RNA vaccines in livestock:

Vaccination is voluntary, not mandatory. The USDA has clearly stated: “There is no requirement or mandate that producers vaccinate their livestock for any disease. It is a personal and business decision left up to the producer and will remain that way”^[8]^[9].
Scientific evidence does not support concerns about RNA transfer to meat products. Dr. Rod Johnson notes: “The likelihood that mRNA from a vaccine would be present in animal protein is remote and not supported by science”^[6].
Penny Riggs, associate professor of animal science at Texas A&M, has characterized claims about mRNA from vaccines transferring to consumers through meat as “fearmongering and misinformation”^[9].

Future Directions in Livestock mRNA Vaccine Development

Research continues on developing true mRNA vaccines for livestock that more closely resemble the human COVID-19 vaccines. Scientists are exploring self-amplifying mRNA-lipid nanoparticle vaccines for diseases like African Swine Fever and Classical Swine Fever^[10]. Additionally, researchers are developing mRNA vaccines targeting Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus (HP-PRRSV)^[11].

The potential benefits of such technology have been noted by industry experts. According to the Indiana Farm Bureau, “mRNA vaccines could protect human health in cases involving zoonotic diseases, which are diseases that can be transmitted from animals to humans”^[2].

Conclusion

The evidence confirms that RNA-based vaccine technology is actively used in swine production through Merck’s SEQUIVITY platform, which has been implemented for over a decade. While this technology belongs to the broader RNA vaccine category, experts distinguish it from the specific mRNA approach used in human COVID-19 vaccines. Both approaches aim to stimulate immune responses using RNA technology, but with different specific mechanisms.

Scientific experts consistently refute concerns about RNA from vaccines persisting in meat products or posing risks to consumers. As research continues on developing more sophisticated mRNA vaccines for livestock, regulatory bodies maintain that vaccination remains a voluntary choice for producers, based on veterinary guidance and specific herd health needs.

⁂

Livestock meat: mRNA inside!

Related Posts:

Submit a Comment Cancel reply